Luyan PharmaLtd マネジメント

マネジメント基準チェック /34

Luyan PharmaLtd's CEO is Jinxiang Wu, appointed in Sep 2008, has a tenure of 16.17 years. directly owns 1.24% of the company’s shares, worth CN¥40.91M. The average tenure of the management team and the board of directors is 5.6 years and 7.1 years respectively.

主要情報

Jinxiang Wu

最高経営責任者

CN¥2.1m

報酬総額

CEO給与比率	n/a
CEO在任期間	16.2yrs
CEOの所有権	1.2%
経営陣の平均在職期間	5.6yrs
取締役会の平均在任期間	7.1yrs

経営陣の近況

Recent updates

The Returns On Capital At Luyan PharmaLtd (SZSE:002788) Don't Inspire Confidence

Sep 30

CEO（最高経営責任者

Jinxiang Wu (62 yo)

16.2yrs

在職期間

CN¥2,146,400

報酬

Mr. Jinxiang Wu serves as the Chairman of the Board of Directors and General Manager at Luyan Pharma Co.,Ltd. (formerly known as Luyan (Fujian) Pharma Co. Ltd.) Mr. Wu serves as Executive Director of Xiame...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jinxiang Wu	Chairman & GM	16.2yrs	CN¥2.15m	1.24% CN¥ 40.9m
Di Wu	Deputy GM & Vice Chairman	7.1yrs	CN¥1.54m	データなし
Zheng Zeng	Financial Director & Accounting Supervisor	1.1yrs	CN¥58.10k	データなし
Lei Ming	Deputy GM	no data	CN¥1.97m	0.12% CN¥ 4.1m
Qizhuan Xu	Assistant to Chairman & Director	1.8yrs	CN¥110.00k	データなし
Quanqing Ye	Secretary	5.2yrs	CN¥961.30k	データなし
Ming Guo Zhu	Deputy General Manager	15.8yrs	CN¥1.95m	0.26% CN¥ 8.5m
Wei Yang Li	Deputy General Manager	15.8yrs	CN¥2.08m	1.04% CN¥ 34.2m
Jun Ying Zhang	Deputy General Manager	15.8yrs	CN¥1.38m	0.92% CN¥ 30.4m
Jin Liu	Deputy General Manager	5.6yrs	CN¥1.67m	データなし
Cuiping Li	Internal Audit Director & Supervisor	no data	データなし	0.00031% CN¥ 10.2k

5.6yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: 002788's management team is seasoned and experienced (5.6 years average tenure).

取締役

名称	ポジション	在職期間	報酬	所有権
Jinxiang Wu	Chairman & GM	16.2yrs	CN¥2.15m	1.24% CN¥ 40.9m
Di Wu	Deputy GM & Vice Chairman	7.1yrs	CN¥1.54m	データなし
Lei Ming	Deputy GM	16.2yrs	CN¥1.97m	0.12% CN¥ 4.1m
Qizhuan Xu	Assistant to Chairman & Director	1.1yrs	CN¥110.00k	データなし
Cuiping Li	Internal Audit Director & Supervisor	12.5yrs	データなし	0.00031% CN¥ 10.2k
Mei Zhen Cai	Chairman of Supervisory Board	13.1yrs	データなし	0.033% CN¥ 1.1m
Jun Long Wu	Independent Director	1.1yrs	CN¥10.00k	データなし
Biyun Lin	Supervisor	7.1yrs	データなし	0.00071% CN¥ 23.4k
Shaoqin Ye	Independent Director	3.5yrs	CN¥98.00k	データなし
Peilin Song	Independent Director	1.1yrs	CN¥10.00k	データなし

7.1yrs

平均在職期間

56.5yo

平均年齢

経験豊富なボード: 002788's board of directors are considered experienced (7.1 years average tenure).

Luyan PharmaLtd マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Luyan Pharma Co.,Ltd., Annual General Meeting, May 07, 2024

Less than half of directors are independent

Less than half of directors are independent

Luyan Pharma Co.,Ltd. Announces Board Appointments

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.18 in 3Q 2023)

Luyan Pharma Co.,Ltd. to Report Q3, 2024 Results on Oct 22, 2024

Investor sentiment improves as stock rises 22%

The Returns On Capital At Luyan PharmaLtd (SZSE:002788) Don't Inspire Confidence

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.28 in 2Q 2023)

Luyan Pharma Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024

Luyan Pharma Co.,Ltd. Announces Final Cash Dividend (A Shares) for the Year 2023, Payable on July 4, 2024

Full year 2023 earnings released: EPS: CN¥0.94 (vs CN¥0.89 in FY 2022)

Luyan Pharma Co.,Ltd., Annual General Meeting, May 07, 2024

Luyan Pharma Co.,Ltd. to Report Q1, 2024 Results on Apr 16, 2024

Investor sentiment deteriorates as stock falls 16%

Luyan Pharma Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Luyan Pharma Co.,Ltd. Announces Board Appointments

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.22 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.25 in 2Q 2022)

Luyan Pharma Co.,Ltd. to Report First Half, 2023 Results on Aug 08, 2023

Luyan Pharma Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 14, 2023

First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.18 in 1Q 2022)

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.22 in 2Q 2021)

Luyan Pharma Co.,Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 06 July 2022

Luyan Pharma Co.,Ltd. Announces Cash Dividend for the Year 2021

Luyan Pharma Co.,Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 1Q 2021)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.25 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.24 in 2Q 2020)

Luyan Pharma Co.,Ltd. Approves Cash Dividend for the Year 2020

Luyan Pharma Co.,Ltd. Announces Profit Distribution Proposal for 2020

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.16 in 1Q 2020)

New 90-day low: CN¥7.18

New 90-day low: CN¥7.81

New 90-day low: CN¥8.41

Third quarter earnings released

Luyan Pharma Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Luyan Pharma Co.,Ltd. has completed a Follow-on Equity Offering in the amount of CNY 338.657765 million.

New 90-day low: CN¥8.54

Earnings released

Luyan Pharma Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥10.93

Luyan Pharma Co.,Ltd. announced a financing transaction

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34